Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ABLI.ST
- Price
- -
- Stock movement up
- +0.00 (0.23%)
- Company name
- Abliva AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 715.67M
- Ent value
- 678.00M
- Price/Sales
- 5223.90
- Price/Book
- 8.16
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -35.15%
- 1 year return
- 183.52%
- 3 year return
- 1.55%
- 5 year return
- -9.93%
- 10 year return
- -38.01%
Last updated: 2025-09-15
DIVIDENDS
ABLI.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5223.90 |
| Price to Book | 8.16 |
| EV to Sales | 4948.89 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.61B |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -0.10 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 46.81M |
| Net receivables | 0.00 |
| Total current assets | 72.12M |
| Goodwill | 0.00 |
| Intangible assets | 11.13M |
| Property, plant and equipment | 0.00 |
| Total assets | 96.84M |
| Accounts payable | 2.61M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 9.03M |
| Total liabilities | 9.13M |
| Shareholder's equity | 87.71M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ABLI.ST | S&P500 | |
| Current price drop from All-time high | -99.45% | -7.47% |
| Highest price drop | -99.86% | -19.00% |
| Date of highest drop | 27 Jun 2024 | 8 Apr 2025 |
| Avg drop from high | -76.85% | -2.76% |
| Avg time to new high | 87 days | 5 days |
| Max time to new high | 2672 days | 89 days |
COMPANY DETAILS
Marketcap
715.67M
Marketcap category
Small-cap
Description
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children's Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden. As of February 7, 2025, Abliva AB (publ) operates as a subsidiary of Pharming Technologies B.V.
Employees
6
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found